Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 82
Filter
1.
Neuropsychiatr ; 24(2): 67-87, 2010.
Article in German | MEDLINE | ID: mdl-20605003

ABSTRACT

The Austrian Alzheimer Society developed evidence-based guidelines based on a systematic literature search and criteria-guided assessment with subsequent transparent determination of grades of clinical recommendation. The authors evaluated currently available therapeutic approaches for the most common forms of dementia and focused on diagnosis and pharmacological intervention, taking into consideration the situation in Austria. The purpose of these guidelines is the rational and cost-effective use of diagnostic and therapeutic measures in dementing illnesses. Users are physicians and all other providers of care for patients with dementia in Austria.


Subject(s)
Dementia/diagnosis , Dementia/drug therapy , Evidence-Based Medicine , Nootropic Agents/therapeutic use , Aged , Aged, 80 and over , Amino Acids/adverse effects , Amino Acids/therapeutic use , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/therapeutic use , Cognition Disorders/diagnosis , Cognition Disorders/drug therapy , Cross-Sectional Studies , Dementia/epidemiology , Dementia/etiology , Drug Therapy, Combination , Female , Ginkgo biloba , Humans , Incidence , Life Style , Long-Term Care , Male , Medication Adherence , Memantine/adverse effects , Memantine/therapeutic use , Middle Aged , Plant Extracts/adverse effects , Plant Extracts/therapeutic use , Population Dynamics , Psychotropic Drugs/adverse effects , Psychotropic Drugs/therapeutic use , Randomized Controlled Trials as Topic
2.
Nervenarzt ; 73(8): 779-84, 2002 Aug.
Article in German | MEDLINE | ID: mdl-12242968

ABSTRACT

We report the case of a 69-year-old patient referred to our clinic because of mania. When examined by neuroradiological imaging, there were lesions seen appearing and disappearing in different regions of the brain during a period of 2 months. Differential diagnosis of these changing lesions, progressive severe illness, and the role of glucocorticoid therapy concerning these lesions are discussed. The diagnosis of primary CNS lymphoma of the B-cell type could not made sure until autopsy.


Subject(s)
Bipolar Disorder/diagnosis , Brain Neoplasms/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Non-Hodgkin/diagnosis , Aged , Biopsy , Bipolar Disorder/drug therapy , Bipolar Disorder/pathology , Brain/pathology , Brain Neoplasms/drug therapy , Brain Neoplasms/pathology , Diagnosis, Differential , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Male , Methylprednisolone/therapeutic use , Neurologic Examination/drug effects , Tomography, X-Ray Computed
3.
Nervenarzt ; 72(10): 794-7, 2001 Oct.
Article in German | MEDLINE | ID: mdl-11688182

ABSTRACT

The article describes the development of symptoms in a 40-year-old female patient who is a symptomatic carrier of X-linked adrenoleucodystrophy (ALD). ALD is characterized by impaired peroxisomal beta-oxidation of very long chain fatty acids and is associated with mutations of the ALD gene, resulting in a defective peroxisomal membrane-transport protein. Our patient's symptoms are identical to those found in multiple sclerosis, showing spastic paraparesis of the lower limbs with marked sensory deficits, visual disturbances in the right eye, and bladder difficulties. Visual and auditory evoked potentials were pathological, and a cranial MRI revealed multiple periventrical white-matter lesions. We found increased intrathecal immunoglobulin production. Diagnosis was established by high concentrations of very long chain fatty acids in serum and in dermal fibroblasts after the same was found in our patient's son. In familial multiple sclerosis, ALD should be excluded in male and female patients.


Subject(s)
Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/cerebrospinal fluid , Adrenoleukodystrophy/genetics , Adult , Diagnosis, Differential , Evoked Potentials , Fatty Acids/metabolism , Female , Fibroblasts/metabolism , Heterozygote , Humans , Immunoglobulins/cerebrospinal fluid , Magnetic Resonance Imaging , Multiple Sclerosis/diagnosis , Phenotype
4.
Med Hypotheses ; 57(4): 491-6, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11601877

ABSTRACT

Advances in neuroradiological and neurosurgical techniques have lead to a growing interest in functional neurosurgical interventions for medically intractable movement disorders. The majority of these procedures are performed in patients with hypokinetic movement disorders, especially Parkinson's disease. However, relatively few interventions were done in hyperkinetic disorders such as Huntington's disease (HD), mainly owing to the lack of an adequate target nucleus. We have recently described the case of a reversible chorea in a genetically confirmed HD patient. We subsequently identified a marked bilateral degeneration of the substantia nigra as the probable reason for choreatic cessation. We therefore suggest that primary striatal atrophy causing hyperkinesia and secondary substantia nigra atrophy favouring hypokinesia were balanced in this patient, thus resulting in a close-to-physiologic GABAergic basal ganglia output. We postulate that deep brain stimulation of the substantia nigra pars compacta may ameliorate hyperkinesia in choreatic movement disorders, thus representing the first effective therapy in Huntington's chorea. Several lines of evidence in recent neurophysiological research support our hypothesis and are discussed below.


Subject(s)
Huntington Disease/surgery , Substantia Nigra/surgery , Humans , Huntington Disease/physiopathology , Substantia Nigra/physiopathology
9.
Nervenarzt ; 71(4): 311-5, 2000 Apr.
Article in German | MEDLINE | ID: mdl-10795100

ABSTRACT

The article describes the development of symptoms in a 59-year-old patient. Dyskinesia and speech disorder were the only clinical features in the beginning. Increased immunological parameters and only slight hypokinetic-rigid signs for a long time made the diagnostical and therapeutical process more difficult, as well as atypical findings in neuroimaging techniques. Corticobasal degeneration was diagnosed about 6 years after onset of clinical symptoms.


Subject(s)
Basal Ganglia Diseases/complications , Basal Ganglia Diseases/diagnosis , Cerebral Cortex/pathology , Dyskinesias/etiology , Neurodegenerative Diseases/complications , Neurodegenerative Diseases/diagnosis , Speech Disorders/etiology , Animals , Basal Ganglia Diseases/diagnostic imaging , Basal Ganglia Diseases/pathology , Cerebral Cortex/diagnostic imaging , Diagnosis, Differential , Disease Progression , Dominance, Cerebral , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/pathology , Pick Disease of the Brain/diagnosis , Tomography, Emission-Computed , Tomography, Emission-Computed, Single-Photon
SELECTION OF CITATIONS
SEARCH DETAIL